U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07706010) titled 'Cardiovascular Risk in T2DM With MAFLD: A Cohort Study' on July 10.
Brief Summary: This study aims to address the following key scientific question by establishing a large-scale, high-standard clinical cohort: the independent contribution of MASLD and its progression to liver fibrosis on cardiovascular outcomes in patients with T2DM, after excluding the confounding effects of traditional cardiovascular risk factors. Its technical value lies in utilizing prospective follow-up data combined with a multivariable competing risks model to develop and validate a cardiovascular risk prediction and early warning system tailored for Chinese ...